Clinical trial
Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for…
NCT00452881 · National Cancer Center, Korea, Other · Unknown status
Key facts
| NCT number | NCT00452881 |
|---|---|
| Title | Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC |
| Official title | A Randomized Phase II Study Adjuvant Gemcitabine And Oxaliplatin Versus Gemcitabine and Cisplatin for Completely Resected Stage IB, II or IIIA Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Center, Korea, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, Oxaliplatin, Cisplatin |
| Enrollment | 151 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Dec 1, 2014 |
| First posted | Mar 28, 2007 |
| Last update posted | Oct 25, 2010 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: